Nifty
Sensex
:
:
13055.15
44523.02
128.70 (1.00%)
445.87 (1.01%)

Pharmaceuticals & Drugs - API

Rating :
71/99  (View)

BSE: 541540 | NSE: SOLARA

1128.75
49.00 (4.54%)
24-Nov-2020 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  1087.00
  •  1134.00
  •  1083.40
  •  1079.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  150199
  •  1695.37
  •  1255.00
  •  364.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,048.11
  • 25.60
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,698.12
  • 0.18%
  • 2.74

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.24%
  • 7.32%
  • 13.89%
  • FII
  • DII
  • Others
  • 12.2%
  • 4.20%
  • 18.15%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 33.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 32.83

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 570.62

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
398
351
13%
348
330
6%
297
385
-23%
344
356
-4%
Expenses
300
283
6%
265
266
-1%
247
321
-23%
266
294
-10%
EBITDA
98
68
44%
84
64
32%
50
65
-23%
78
62
25%
EBIDTM
25%
19%
24%
19%
14%
14%
23%
17%
Other Income
6
5
24%
5
4
5%
12
7
83%
6
4
57%
Interest
19
20
-5%
20
19
6%
20
22
-6%
19
23
-18%
Depreciation
28
24
17%
26
23
15%
24
23
2%
24
21
12%
PBT
57
29
95%
42
26
60%
18
26
-32%
41
22
87%
Tax
0
0
-73%
0
0
0
0
0
-
0
0
0
PAT
57
29
96%
42
26
60%
18
26
-32%
41
22
87%
PATM
14%
8%
12%
8%
7%
7%
12%
6%
EPS
15.84
8.07
96%
11.81
7.40
60%
4.97
7.32
-32%
11.54
6.17
87%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 20
Mar 19
Mar 18
Net Sales
1,386
1,322
1,409
560
Net Sales Growth
-3%
-6%
151%
 
Cost Of Goods Sold
5,116
599
724
293
Gross Profit
-3,730
723
685
267
GP Margin
-269%
55%
49%
48%
Total Expenditure
1,077
1,076
1,210
501
Power & Fuel Cost
-
78
79
31
% Of Sales
-
6%
6%
6%
Employee Cost
-
204
188
72
% Of Sales
-
15%
13%
13%
Manufacturing Exp.
-
95
102
48
% Of Sales
-
7%
7%
9%
General & Admin Exp.
-
48
36
15
% Of Sales
-
4%
3%
3%
Selling & Distn. Exp.
-
25
31
18
% Of Sales
-
2%
2%
3%
Miscellaneous Exp.
-
28
50
24
% Of Sales
-
2%
4%
4%
EBITDA
309
245
198
59
EBITDA Margin
22%
19%
14%
11%
Other Income
29
28
12
2
Interest
78
78
82
25
Depreciation
102
80
71
36
PBT
158
115
58
0
Tax
0
0
-2
0
Tax Rate
0%
0%
-3%
-70%
PAT
158
115
60
0
PAT before Minority Interest
158
115
59
0
Minority Interest
0
0
0
0
PAT Margin
11%
9%
4%
0%
PAT Growth
52%
93%
15,561%
 
EPS
44.16
32.01
16.62
0.11

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Shareholder's Funds
1,086
956
764
Share Capital
27
26
25
Total Reserves
958
824
739
Non-Current Liabilities
333
344
315
Secured Loans
233
225
243
Unsecured Loans
0
0
0
Long Term Provisions
33
29
24
Current Liabilities
730
656
738
Trade Payables
216
244
313
Other Current Liabilities
157
192
90
Short Term Borrowings
354
214
330
Short Term Provisions
3
4
5
Total Liabilities
2,153
1,960
1,821
Net Block
1,368
1,189
1,063
Gross Block
1,581
1,309
1,100
Accumulated Depreciation
213
121
36
Non Current Assets
1,481
1,312
1,214
Capital Work in Progress
40
40
71
Non Current Investment
29
30
23
Long Term Loans & Adv.
41
36
46
Other Non Current Assets
3
17
9
Current Assets
672
648
608
Current Investments
0
0
0
Inventories
280
214
188
Sundry Debtors
227
289
263
Cash & Bank
57
76
47
Other Current Assets
109
49
75
Short Term Loans & Adv.
69
20
35
Net Current Assets
-58
-7
-130
Total Assets
2,153
1,960
1,821

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Cash From Operating Activity
244
166
49
PBT
115
58
0
Adjustment
170
148
63
Changes in Working Capital
-16
-25
-11
Cash after chg. in Working capital
269
181
52
Interest Paid
0
0
0
Tax Paid
-24
-14
-3
Other Direct Exp. Paid
0
0
0
Extra & Other Items
0
0
0
Cash From Investing Activity
-359
-116
-85
Net Fixed Assets
-273
-178
Net Investments
1
-7
Others
-87
69
Cash from Financing Activity
95
-23
68
Net Cash Inflow / Outflow
-20
27
31
Opening Cash & Equivalents
76
46
0
Closing Cash & Equivalent
56
76
46

Financial Ratios

Standalone /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Book Value (Rs.)
367
330
310
ROA
6%
3%
0%
ROE
12%
7%
0%
ROCE
12%
10%
2%
Fixed Asset Turnover
0.91
1.17
0.51
Receivable days
71
71
171
Inventory Days
68
52
122
Payable days
77
85
229
Cash Conversion Cycle
63
38
65
Total Debt/Equity
0.72
0.63
0.83
Interest Cover
2
2
1

Annual Reports:


News Update


  • CRISIL upgrades ratings of Solara Active Pharma Sciences
    25th Sep 2020, 16:03 PM

    CRISIL has upgraded Solara Active Pharma Sciences’ long term rating to A-/Stable

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.